Department of Medicine 2-Grosshadern, University of Munich, Munich, Germany.
Copyright © 2015 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST: KGP has received research support by Genzyme, Merck Sharp & Dohme, and Novartis and honoraria for presentations, advisory board activities or DMC acitivities by Aegerion, Amgen, Chiesi, Fresenius, Genzyme, Kaneka, Kowa, Merck Sharp & Dohme, Novartis, Regeneron, Roche, Sanofi.
Statin | OR | 95% CI |
---|---|---|
Atorvastatin | 1.14 | 0.89-1.46 |
Simvastatin | 1.11 | 0.97-1.26 |
Rosuvastatin | 1.18 | 1.04-1.33 |
Pravastatin | 1.03 | 0.90-1.19 |
Lovastatin | 0.98 | 0.70-1.38 |
Overall | 1.09 | 1.02-1.17 |
Adjusted OR | |
---|---|
Not affected | 1 |
All affected | 0.49 |
apoB mutation | 0.65 |
LDL-R mutation | 0.45 |
LDL-R defective | 0.49 |
LDL-R negative | 0.38 |